Oscar Health, Inc. (OSCR)
NYSE: OSCR · IEX Real-Time Price · USD
15.25
+0.29 (1.94%)
At close: Jul 19, 2024, 4:00 PM
15.48
+0.23 (1.51%)
Pre-market: Jul 22, 2024, 7:38 AM EDT
Oscar Health Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Oscar Health stock have an average target of 19.75, with a low estimate of 7.50 and a high estimate of 28. The average target predicts an increase of 29.51% from the current stock price of 15.25.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Oscar Health stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 2 | 3 | 3 | 4 | 5 | 5 |
| Hold | 3 | 3 | 3 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $25 | Buy | Initiates | $25 | +63.93% | Jun 26, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $24 → $27 | Buy | Maintains | $24 → $27 | +77.05% | Jun 12, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Hold Downgrades $25 → $21 | Strong Buy → Hold | Downgrades | $25 → $21 | +37.70% | May 30, 2024 |
| Baird | Baird | Buy Initiates $28 | Buy | Initiates | $28 | +83.61% | May 30, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $22 → $25 | Strong Buy | Maintains | $22 → $25 | +63.93% | May 20, 2024 |
Financial Forecast
Revenue This Year
8.83B
from 5.86B
Increased by 50.66%
Revenue Next Year
11.08B
from 8.83B
Increased by 25.48%
EPS This Year
0.03
from -1.22
EPS Next Year
0.58
from 0.03
Increased by 1,912.00%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 9.5B | 12.2B | 15.3B | 18.9B |
| Avg | 8.8B | 11.1B | 13.3B | 16.4B |
| Low | 8.2B | 10.1B | 12.0B | 13.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 61.5% | 37.6% | 38.1% | 41.6% |
| Avg | 50.7% | 25.5% | 20.4% | 22.9% |
| Low | 39.6% | 14.2% | 8.2% | 4.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 0.30 | 0.98 | 1.53 | 2.89 |
| Avg | 0.03 | 0.58 | 1.32 | 2.45 |
| Low | -0.10 | 0.31 | 0.97 | 2.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 3,279.3% | 163.7% | 119.0% |
| Avg | - | 1,912.0% | 126.8% | 85.7% |
| Low | - | 985.2% | 66.9% | 52.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.